GlaxoSmithKline, Ranbaxy settle Valtrex patent dispute

Share this article:

Generics drug firm Ranbaxy Laboratories said it has reached an agreement with GlaxoSmithKline resulting in a dismissal of US patent litigation regarding Glaxo's herpes pill Valtrex (valacyclovir hydrochloride).

Under the agreement, Ranbaxy will be allowed to introduce its generic version of Valtrex in the US in late 2009 and will have 180 days of sales product exclusivity.

In early February 2007, Ranbaxy received a final approval from the FDA to market and manufacture valacyclovir hydrochloride tablets.

Glaxo's Valtrex patent is set to expire in 2009 in the US and most of Europe. The drug was first introduced in 1995.

Total global sales of Valtrex were around $1.3 billion for 2006.

 

Share this article:

Email Newsletters

More in News

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...

Pfizer Q2 sales slip, but still beat expectations

Pfizer Q2 sales slip, but still beat expectations

Patent losses and lost co-promotion agreements put a dent in sales.

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?